Dirk Völkel

761 total citations
13 papers, 538 citations indexed

About

Dirk Völkel is a scholar working on Immunology, Molecular Biology and Cellular and Molecular Neuroscience. According to data from OpenAlex, Dirk Völkel has authored 13 papers receiving a total of 538 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Immunology, 5 papers in Molecular Biology and 2 papers in Cellular and Molecular Neuroscience. Recurrent topics in Dirk Völkel's work include Macrophage Migration Inhibitory Factor (6 papers), Prion Diseases and Protein Misfolding (4 papers) and Neurological diseases and metabolism (2 papers). Dirk Völkel is often cited by papers focused on Macrophage Migration Inhibitory Factor (6 papers), Prion Diseases and Protein Misfolding (4 papers) and Neurological diseases and metabolism (2 papers). Dirk Völkel collaborates with scholars based in Austria, Switzerland and Germany. Dirk Völkel's co-authors include Klaus F. Zimmermann, Randolf J. Kerschbaumer, Gerhard Antoine, Friedrich Scheiflinger, Barbara Plaimauer, Friedrich Scheiflinger, Bernhard Lämmle, Miha Furlan, Hans Peter Schwarz and Michael Thiele and has published in prestigious journals such as Journal of Biological Chemistry, Blood and European Journal of Biochemistry.

In The Last Decade

Dirk Völkel

13 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Völkel Austria	10	374	136	131	77	67	13	538
Clare Hassett United States	6	103 0.3×	28 0.2×	135 1.0×	15 0.2×	63 0.9×	9	374
L M Wood United States	6	316 0.8×	146 1.1×	86 0.7×	11 0.1×	53 0.8×	7	454
Samantha A. Chalmers United States	13	273 0.7×	26 0.2×	98 0.7×	10 0.1×	38 0.6×	25	517
Zoltán Doleschall Hungary	10	167 0.4×	100 0.7×	118 0.9×	7 0.1×	21 0.3×	20	358
Guosu Wang United Kingdom	12	234 0.6×	59 0.4×	180 1.4×	8 0.1×	10 0.1×	13	506
Simone Orlando Italy	6	196 0.5×	52 0.4×	137 1.0×	13 0.2×	7 0.1×	6	401
Martina Meßner Germany	8	200 0.5×	36 0.3×	125 1.0×	11 0.1×	9 0.1×	9	434
M. Anna Kowalska United States	13	106 0.3×	295 2.2×	156 1.2×	18 0.2×	5 0.1×	18	578
Julia T. Tanassi Denmark	10	164 0.4×	18 0.1×	186 1.4×	18 0.2×	13 0.2×	15	414
C P Chiu United States	5	202 0.5×	44 0.3×	234 1.8×	16 0.2×	5 0.1×	8	543

Countries citing papers authored by Dirk Völkel

Since Specialization

Citations

This map shows the geographic impact of Dirk Völkel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Völkel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Völkel more than expected).

Fields of papers citing papers by Dirk Völkel

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Völkel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Völkel. The network helps show where Dirk Völkel may publish in the future.

Co-authorship network of co-authors of Dirk Völkel

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Völkel. A scholar is included among the top collaborators of Dirk Völkel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Völkel. Dirk Völkel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

13 of 13 papers shown

Mahalingam, Devalingam, Manish R. Patel, Jasgit C. Sachdev, et al.. (2020). Phase I study of imalumab (BAX69), a fully human recombinant antioxidized macrophage migration inhibitory factor antibody in advanced solid tumours. British Journal of Clinical Pharmacology. 86(9). 1836–1848. 49 indexed citations

Thiele, Michael, Patrice Douillard, Dirk Völkel, et al.. (2016). Oxidized macrophage migration inhibitory factor is a potential new tissue marker and drug target in cancer. Oncotarget. 7(45). 73486–73496. 27 indexed citations

Thiele, Michael, Thorsten Hagemann, Michael Freissmuth, et al.. (2014). 811: Fully human antibodies specific for oxidized macrophage migration inhibitory factor (oxMIF) exhibit anti-cancer activity in animal models. European Journal of Cancer. 50. S196–S196. 1 indexed citations

Freissmuth, Michael, Dirk Völkel, Michael Thiele, et al.. (2013). Human Anti-Macrophage Migration Inhibitory Factor Antibodies Inhibit Growth of Human Prostate Cancer Cells In Vitro and In Vivo. Molecular Cancer Therapeutics. 12(7). 1223–1234. 59 indexed citations

Kerschbaumer, Randolf J., Manfred Rieger, Dirk Völkel, et al.. (2012). Neutralization of Macrophage Migration Inhibitory Factor (MIF) by Fully Human Antibodies Correlates with Their Specificity for the β-Sheet Structure of MIF. Journal of Biological Chemistry. 287(10). 7446–7455. 51 indexed citations

Kerschbaumer, Randolf J., Manfred Rieger, Gerhard Antoine, et al.. (2008). Fully human anti-macrophage migration inhibitory factor antibodies as potential therapeutics for sepsis and septic shock. Critical Care. 12(Suppl 5). P15–P15. 2 indexed citations

Völkel, Dirk, Barbara Plaimauer, G. Antoine, et al.. (2005). Cloning, expression and functional characterization of the full‐length murine ADAMTS13. Journal of Thrombosis and Haemostasis. 3(5). 1064–1073. 9 indexed citations

Zimmermann, Klaus F., et al.. (2004). Native Versus Recombinant High-Mobility Group B1 Proteins: Functional Activity In Vitro. Inflammation. 28(4). 221–229. 51 indexed citations

Völkel, Dirk, Klaus F. Zimmermann, Andreas Breitwieser, et al.. (2003). Immunochemical detection of prion protein on dipsticks prepared with crystalline bacterial cell‐surface layers. Transfusion. 43(12). 1677–1682. 11 indexed citations

10.

Plaimauer, Barbara, Klaus F. Zimmermann, Dirk Völkel, et al.. (2002). Cloning, expression, and functional characterization of the von Willebrand factor–cleaving protease (ADAMTS13). Blood. 100(10). 3626–3632. 184 indexed citations

11.

Völkel, Dirk, Klaus F. Zimmermann, Inga Zerr, et al.. (2001). C‐reactive protein and IL‐6: new marker proteins for the diagnosis of CJD in plasma?. Transfusion. 41(12). 1509–1514. 22 indexed citations

12.

Völkel, Dirk, Klaus F. Zimmermann, Inga Zerr, et al.. (2001). Immunochemical determination of cellular prion proteinin plasma from healthy subjects and patients withsporadic CJD or other neurologic diseases. Transfusion. 41(4). 441–448. 52 indexed citations

13.

Völkel, Dirk, Wulf Blankenfeldt, & Dietmar Schomburg. (1998). Large‐scale production, purification and refolding of the full‐length cellular prion protein from Syrian golden hamster in Escherichia coli using the glutathione S‐transferase‐fusion system. European Journal of Biochemistry. 251(1-2). 462–471. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact